News & events
Get to Know Us
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
July 9, 2020
Unconventional Weapon in the War on Cancer Revealed
June 10, 2019
Immunicom Announces First Patient Enrollment in Multi-Center, Triple-Negative Breast Cancer Clinical Trial
May 14, 2018
Immunicom’s Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
Press Releases
October 7, 2021
Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy
September 28, 2021
Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award
September 21, 2021
Immunicom Introduces 2nd Product of Immunopheresis® Therapy Platform Designed to Suppress Cancer Progression and Overcome Therapeutic Resistance
September 14, 2021
Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team